Matthew Sikora, PhD

Publications

• Sikora MJ. Family Matters: Collaboration and Conflict Among the Steroid Receptors Raises a Need for Group Therapy. Endocrinology. 2016 Dec;157(12):4553-4560. PubMed PMID: 27835038
• Martin LA, Ribas R, Simigdala N, Schuster E, Pancholi S, Tenev T, Gellert P, Buluwela L, Harrod A, Thornhill A, Nikitorowicz-Buniak J, Bhamra A, Turgeon MO, Poulogiannis G, Gao Q, Martins V, Hills M, Garcia-Murillas I, Fribbens C, Patani N, Li Z, Sikora MJ, Turner N, Zwart W, Oesterreich S, Carroll J, Ali S, Dowsett M. Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nat Commun. 2017 Nov 30;8(1):1865. PubMed PMID: 29192207
• Hertz DL, Kidwell KM, Hilsenbeck SG, Oesterreich S, Osborne CK, Philips S, Chenault C, Hartmaier RJ, Skaar TC, Sikora MJ, Rae JM. CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat. 2017 Nov;166(1):277-287. PubMed PMID: 28730340
• Andersen CL, Sikora MJ, Boisen MM, Ma T, Christie A, Tseng G, Park Y, Luthra S, Chandran U, Haluska P, Mantia-Smaldone GM, Odunsi K, McLean K, Lee AV, Elishaev E, Edwards RP, Oesterreich S. Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens. Clin Cancer Res. 2017 Jul 15;23(14):3802-3812. PubMed PMID: 28073843
• Hsu JY, Sikora MJ. CRISPR Fish Reel in Novel Roles for Estrogen Receptors in Reproduction. Endocrinology. 2017 Jul 1;158(7):2082-2083. PubMed PMID: 28881866
• Andersen CL, Boisen MM, Sikora MJ, Ma T, Tseng G, Suryawanshi S, Vlad A, Elishaev E, Edwards RP, Oesterreich S. The Evolution of Estrogen Receptor Signaling in the Progression of Endometriosis to Endometriosis-Associated Ovarian Cancer. Horm Cancer. 2018 Dec;9(6):399-407. PubMed PMID: 30302736
• Wnt family member 4 (WNT4) and WNT3A activate cell-autonomous Wnt signaling independent of porcupine O-acyltransferase or Wnt secretion. Rao DM, et al. J Biol Chem 2019. Among authors: Sikora MJ. PubMed PMID: 31740580.
• FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype. Levine KM, et al. NPJ Breast Cancer 2019. Among authors: Sikora MJ. PubMed PMID: 31263748. PubMed Central PMCID: PMC6597581.
• Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma. Cao L, et al. Cancer Lett 2019. Among authors: Sikora MJ. PubMed PMID: 31229512. PubMed Central PMCID: PMC6682463.
• Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Yamamoto TM, et al. Mol Carcinog 2019. Among authors: Sikora MJ. PubMed PMID: 31219654.
• Tasdemir N, Bossart EA, Li Z, Zhu L, Sikora MJ, Levine KM, Jacobsen BM, Tseng GC, Davidson NE, Oesterreich S. Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. Cancer Res. 2018 Nov 1;78(21):6209-6222. PubMed PMID: 30228172
• SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma. Bossart EA, et al. Breast Cancer Res Treat 2019. Among authors: Sikora MJ. PubMed PMID: 30798422. PubMed Central PMCID: PMC6625318.
• Estrogen controls mTOR signaling and mitochondrial function via WNT4 in lobular carcinoma. Rao, DM et al. Among authors: Sikora MJ. bioRxiv 684530; doi: https://doi.org/10.1101/684530
• Du T, Sikora MJ, Levine KM, Tasdemir N, Riggins RB, Wendell SG, Van Houten B, Oesterreich S. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer. Breast Cancer Res. 2018 Sep 4;20(1):106. PubMed PMID: 30180878
• Rao, D.M., Ferguson, R.L., Yamamoto, T.M., Bitler, B.G., Sikora, M.J.* WNT4 and WNT3A activate cell autonomous Wnt signaling independent of secretion. bioRxiv. 2018 May 30; 333906. DOI: https://doi.org/10.1101/333906
• Yamamoto, T.M., McMellen, A., Watson, Z.L., Aguilera, J., Sikora, M.J., Ferguson, R., Nurmemmedov, E., Thakar, T., George-Lucian, M., Kim, H., Cittelly, D.M., Wilson, H., Behbakht, K., Bitler, B.G. Targeting Wnt Signaling To Overcome PARP Inhibitor Resistance. bioRxiv. 2018 July 27; 378463. DOI: https://doi.org/10.1101/378463
• Shackleford MT, Rao DM, Bordeaux EK, Hicks HM, Towers CG, Sottnik JL, Oesterreich S, Sikora MJ. Estrogen Regulation of mTOR Signaling and Mitochondrial Function in Invasive Lobular Carcinoma Cell Lines Requires WNT4. Cancers (Basel). 2020 Oct 12;12(10). PubMed PMID: 33053661
• [Sikora MJ, Jordan KR], Slansky JE, Minic A, Richer JK, Moroney MR, Hu J, Wolsky RJ, Watson ZL, Yamamoto TM, Costello JC, Clauset A, Behbakht K, Kumar TR, Bitler BG. The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval. Clin Cancer Res. 2020 Dec 1;26(23):6362-6373. PubMed PMID: 32928797
• Sreekumar S, Levine KM, Sikora MJ, Chen J, Tasdemir N, Carter D, Dabbs DJ, Meier C, Basudan A, Boone D, McAuliffe PF, Jankowitz RC, Lee AV, Atkinson JM, Oesterreich S. Differential Regulation and Targeting of Estrogen Receptor a Turnover in Invasive Lobular Breast Carcinoma. Endocrinology. 2020 Sep 1;161(9). PubMed PMID: 32609836
• Mediator of DNA damage checkpoint 1 (MDC1) is a novel estrogen receptor co-regulator in invasive lobular carcinoma of the breast Evelyn K. Bordeaux, Joseph L. Sottnik, Sanjana Mehrotra, Sarah E. Ferrara, Andrew E. Goodspeed, James C. Costello, Matthew J. Sikora bioRxiv 2020.12.16.423142; doi: https://doi.org/10.1101/2020.12.16.423142
• Sikora MJ*, Riggins RB*, Madak-Erdogan Z*. Making an IMPACT on career development for early- and mid-career faculty. In press, Endocrinology. *Authors contributed equally, co-corresponding
• Pitzer LM, Moroney MR, Nokoff NJ, Sikora MJ. WNT4 Balances Development vs Disease in Gynecologic Tissues and Women's Health. Endocrinology. 2021 Jul 1;162(7). PubMed PMID: 33963381
• Sottnik JL, Bordeaux EK, Mehrotra S, Ferrara SE, Goodspeed AE, Costello JC, Sikora MJ. Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast. Mol Cancer Res. 2021 Aug;19(8):1270-1282. PubMed PMID: 33947745
• Sikora MJ, Riggins RB, Madak-Erdogan Z. Making an IMPACT on career development for early- and mid-career faculty. Endocrinology. 2021 Jan 7. [Epub ahead of print] PubMed PMID: 33411889
• Li Z, Spoelstra NS, Sikora MJ, Sams SB, Elias A, Richer JK, Lee AV, Oesterreich S. Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer. NPJ Breast Cancer. 2022 May 10;8(1):62. PubMed PMID: 35538119
• Bahnassy S, Sikora MJ, Riggins RB. Unlocking the Mysteries of Lobular Breast Cancer Biology Needs the Right Combination of Preclinical Models. Mol Cancer Res. 2022 Jun 3;20(6):837-840. PubMed PMID: 35276005
• WNT4 executes estrogen regulation of cellular metabolism via intracellular activity at the mitochondria Joseph L. Sottnik, Madeleine T. Shackleford, Shaymaa Bahnassy, Zeynep Madak-Erdogan, Rebecca B. Riggins, Benjamin G. Bitler, Matthew J. Sikora bioRxiv 2022.07.15.499747; doi: https://doi.org/10.1101/2022.07.15.499747
• Li Z, Li T, Yates ME, Wu Y, Ferber A, Chen L, Brown DD, Carroll JS, Sikora MJ, Tseng GC, Oesterreich S, Lee AV. The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer. Cancer Res. 2023 Aug 15;83(16):2656-2674. PubMed PMID: 37272757
• Li Z, Spoelstra NS, Sikora MJ, Sams SB, Elias A, Richer JK, Lee AV, Oesterreich S. Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer. NPJ Breast Cancer. 2022 May 10;8(1):62. PubMed PMID: 35538119
• Bahnassy S, Sikora MJ, Riggins RB. Unlocking the Mysteries of Lobular Breast Cancer Biology Needs the Right Combination of Preclinical Models. Mol Cancer Res. 2022 Jun 3;20(6):837-840. PubMed PMID: 35276005
• WNT4 regulates cellular metabolism via intracellular activity at the mitochondria in breast and gynecologic cancers Joseph L. Sottnik, Madeleine T. Shackleford, Fabian R. Villagomez, Shaymaa Bahnassy, Steffi Oesterreich, Junxiao Hu, Zeynep Madak-Erdogan, Rebecca B. Riggins, Bradley R. Corr, Linda S. Cook, Lindsey S. Treviño, Benjamin G. Bitler, Matthew J. Sikora bioRxiv 2022.07.15.499747; doi: https://doi.org/10.1101/2022.07.15.499747 [Updated June 2023]
• Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breast Joseph L. Sottnik, Madeleine T. Shackleford, Amanda L. Richer, Rui Fu, Jay R. Hesselberth, Matthew J. Sikora bioRxiv 2023.10.29.564555; doi: https://doi.org/10.1101/2023.10.29.564555